Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will present a poster on its Phase 2a BANYAN clinical trial of ...
ALS Nexus 2026, organized by the ALS Association, takes place August 23–26, 2026, bringing together researchers, clinicians, people living with ALS, caregivers, and advocates to accelerate progress ...
Top line data readout expected in late Q3/early Q4 INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary ...
Biotechnology firm Tiziana Life Sciences Ltd. TLSA on Friday revealed promising quantitative PET imaging results from the third patient participating in its Phase 2 clinical trial. The ongoing study ...
BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...
View Tiziana Life Sciences Ltd. TLSA stock quote prices, financial information, real-time forecasts, and company news from CNN.
Detailed price information for Tiziana Life Sciences Ltd (TLSA-Q) from The Globe and Mail including charting and trades.
Tiziana Life Sciences has filed an amendment to get its oral antibody program back on track. After hitting a roadblock with its initial design, Tiziana has expanded the patient population and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results